Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2013

01-06-2013 | short review

Local therapy in prostate cancer—surgery versus radiation

Authors: Isabel Heidegger, MD, Prof. Wolfgang Horninger, MD, Assoc. Prof. Jasmin Bektic, MD

Published in: memo - Magazine of European Medical Oncology | Issue 2/2013

Login to get access

Abstract

Many patients with localized prostate cancer are eligible for more than one treatment option. Currently, both radical prostatectomy (RP) and radiotherapy (RT) are the key treatment options in organ-confined disease. In this review, we provide an overview about oncologic outcomes of both therapy modalities. Additionally, we review studies about patients’ quality of life after therapy as well as common side effects of both therapeutic options.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Actas Urol Esp. 2011;35(9):501–14.PubMedCrossRef
3.
Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982;128(3):502–4.PubMed
4.
Tewari A, Raman JD, Chang P, Rao S, Divine G, Menon M. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology. 2006;68(6):1268–74.PubMedCrossRef
5.
Jeldres C, Suardi N, Perrotte P, Capitanio U, Walz J, Hutterer GC, et al. Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J. 2009;3(1):13–21.PubMed
6.
Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296(22):2683–93.PubMedCrossRef
7.
Gonzalez-San Segundo C, Herranz-Amo F, Alvarez-Gonzalez A, Cuesta-Alvaro P, Gomez-Espi M, Panos-Fagundo E, et al. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control-in search of the optimal treatment. Ann Surg Oncol. 2011;18(10):2980–7.PubMedCrossRef
8.
Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631–8.PubMedCrossRef
9.
Heidegger I, Ladurner M, Skradski V, Klocker H, Schafer G, Horninger W, et al. Adverse pathological findings in needle biopsy Gleason score 6 prostate cancers with low and intermediate preoperative PSA levels following radical prostatectomy. Anticancer Res. 2012;32(12):5481–5.PubMed
10.
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13):2883–91.PubMedCrossRef
11.
Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol. 2012;19(9):836–44.PubMedCrossRef
12.
Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435–48.PubMedCrossRef
13.
Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.PubMedCrossRef
14.
Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys. 2010;76(2):342–8.PubMedCrossRef
15.
Hall JD, Boyd JC, Lippert MC, Theodorescu D. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology. 2003;61(2):402–7.PubMedCrossRef
16.
van Tol-Geerdink JJ, Leer JW, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, et al. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int. 2012. doi: 10.1111/j.1464-410X.2012.11402.x
17.
Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, et al. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005;104(7):1381–90.PubMedCrossRef
18.
Anandadas CN, Clarke NW, Davidson SE, O’Reilly PH, Logue JP, Gilmore L, et al. Early prostate cancer—which treatment do men prefer and why? BJU Int. 2011;107(11):1762–8.PubMedCrossRef
Metadata
Title
Local therapy in prostate cancer—surgery versus radiation
Authors
Isabel Heidegger, MD
Prof. Wolfgang Horninger, MD
Assoc. Prof. Jasmin Bektic, MD
Publication date
01-06-2013
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2013
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0068-x

Other articles of this Issue 2/2013

memo - Magazine of European Medical Oncology 2/2013 Go to the issue

case report

Broken venous catheter straddling in the pulmonary artery

short review

New developments in acute graft-versus-host disease

special report

Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?

review

Biomolecular basis of the role of chronic psychological stress hormone ‘‘glucocorticoid’’ in alteration of cellular immunity during cancer

Report

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

short review

Optimal surveillance strategy of localised testicular non-germ cell sex-cord stromal tumours
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits